Central Nervous System News and Research

RSS

First proton therapy center for New Jersey

Cancer survivors joined representatives from ProCure Treatment Centers, Inc., Princeton Radiation Oncology, and CentraState Healthcare System to break ground on the ProCure Proton Therapy Center in Somerset - the first proton therapy center to be built in the state, located 40 miles from downtown Manhattan.

8 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

Dalfampridine drug for multiple sclerosis now available in the U.S.

A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.

6 Apr 2010

Menstrual stem cells may help in treatment of stroke and central nervous system disorders

Cryo-Cell International, Inc. today announced results of a study published this month in the cover article of Stem Cells and Development showing that stem cells found in menstrual blood may one day be a potential source for stem cell therapies in stroke and other central nervous system disorders.

5 Apr 2010

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).

5 Apr 2010

Scientists identify potential new method for treating sleeping sickness

Scientists have identified a potential new approach to treat human African trypanosomiasis (HAT), commonly known as sleeping sickness, which afflicts "tens of thousands of people in sub-Saharan Africa" annually, IRIN reports. By targeting an enzyme the sleeping sickness parasite needs in order to survive, researchers say they can kill it without causing harm to the patient (4/1).

2 Apr 2010

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended December 31, 2009.

1 Apr 2010

Nation's emergency physicians warn parents about dangers of prescription drug abuse

The nation's emergency physicians are issuing a strong warning to parents about the dangers of prescription drug abuse, which are now the second most abused drugs, after marijuana. Nearly three-quarters of a million people (741,425) needed emergency care in 2006 because of prescription drug abuse.

31 Mar 2010

NeurOp and Bristol-Myers Squibb announce drug discovery collaboration

NeurOp Corporation today announced a collaboration with Bristol-Myers Squibb Company (NYSE: BMY) focused upon the development of NeurOp's proprietary small molecules for use in the treatment of major depression and other central nervous system disorders.

31 Mar 2010

United Anesthesia Services deploys Quantum Clinical Navigation System in Bryn Mawr Hospital

United Anesthesia Services, P.C. has taken the lead in the Pennsylvania marketplace regarding its commitment to patient quality by deploying the Quantum Clinical Navigation System™ in Bryn Mawr Hospital.

31 Mar 2010

Ascent Therapeutics is now Anchor Therapeutics

Ascent Therapeutics announced today that it has adopted a new name — Anchor Therapeutics. Anchor Therapeutics reflects the Company's core technology and its commitment to building solid, dependable value for patients, partners and investors via its proprietary platform technology.

30 Mar 2010

Chakra Biotech completes MYR18.2m Series B investment round

Chakra Biotech Sdn Bhd, a Malaysian based Contract Research Organization, has completed a MYR18.2m Series B funding round. This brings total funding for the company to MYR20.0m. Malaysian Life Sciences Capital Fund Ltd. (MLSCF) and the Malaysian Technology Development Corporation Sdn Bhd (MTDC) participated in the round.

29 Mar 2010

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

In an article published in Nature Genetics today, scientists at the ALS Therapy Development Institute describe how they have linked an unbiased gene expression profiling effort to the identification and successful preclinical testing of a potential novel therapeutic for amyotrophic lateral sclerosis.

29 Mar 2010

Neurologix reports net loss of $13.5M for year ended December 31, 2009

Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, today announced its financial results for the year ended December 31, 2009.

26 Mar 2010

BLS acquires AMPAKINE compounds from Cortex Pharmaceuticals

Biovail Corporation today announced that its subsidiary, Biovail Laboratories International SRL, has acquired certain AMPAKINE® compounds, including associated intellectual property, from Cortex Pharmaceuticals, Inc. for use in the field of respiratory depression, a brain-mediated breathing disorder.

26 Mar 2010

Biogen Idec and Elan begin comparative trial of MS treatments

Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI® (natalizumab) from Copaxone® (glatiramer acetate) or Rebif® (interferon beta-1a) in patients with relapsing remitting multiple sclerosis.

25 Mar 2010

Research could pave way for new generation of painkillers

An international group of scientists led by Dr Nikita Gamper of the University's Faculty of Biological Sciences has discovered how two proteins play a key role in the way we feel pain, offering new targets on which drug development can be focused.

25 Mar 2010

SAMHSA study shows how psychiatric drugs prescribed for medical conditions

A new study sponsored by the Substance Abuse and Mental Health Services Administration outlines the conditions that physicians around the country reported treating with psychiatric drugs such as antipsychotics, antidepressants, and anti-anxiety drugs.

23 Mar 2010

Rexahn Pharmaceuticals forms Parkinson’s Disease SAB to develop strategy for Serdaxin

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the formation of its Parkinson’s Disease Scientific Advisory Board (SAB), featuring some of the leading medical researchers in neurology.

22 Mar 2010

AARDA launches campaign on family AQ

In honor of the designation of March as National Autoimmune Disease Awareness Month by the U.S. Senate on March 4, 2010, the American Autoimmune Related Diseases Association (AARDA) wants to help you learn your family's AQ. AQ is a play on IQ that stands for Autoimmune Quotient. It's about knowing how likely you or a loved one is to develop an autoimmune disease, based on the prevalence of these diseases and your family history. The campaign features AARDA National Spokesperson and Actress Kellie Martin, best known for her memorable roles on "E.R." and "Life Goes On."

22 Mar 2010

Central Nervous System News and Research

First proton therapy center for New Jersey

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Dalfampridine drug for multiple sclerosis now available in the U.S.

Menstrual stem cells may help in treatment of stroke and central nervous system disorders

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Scientists identify potential new method for treating sleeping sickness

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

Nation's emergency physicians warn parents about dangers of prescription drug abuse

NeurOp and Bristol-Myers Squibb announce drug discovery collaboration

United Anesthesia Services deploys Quantum Clinical Navigation System in Bryn Mawr Hospital

Ascent Therapeutics is now Anchor Therapeutics

Chakra Biotech completes MYR18.2m Series B investment round

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

Neurologix reports net loss of $13.5M for year ended December 31, 2009

BLS acquires AMPAKINE compounds from Cortex Pharmaceuticals

Biogen Idec and Elan begin comparative trial of MS treatments

Research could pave way for new generation of painkillers

SAMHSA study shows how psychiatric drugs prescribed for medical conditions

Rexahn Pharmaceuticals forms Parkinson’s Disease SAB to develop strategy for Serdaxin

AARDA launches campaign on family AQ

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News